Without a trace of preparation, a bull stock suddenly fell to the limit!
This morning, after the opening, it has been trading horizontally around yesterday's closing price, rising and falling slightly. Near 10:30, it suddenly fell to the limit. In the morning, it closed at 25.58 yuan, down 9.99%, the turnover was 789 million yuan, and the turnover rate was 1.94%. By the end of the day, there were still 4.328 million shares on the limit.
On the face of the news, at 9: 00 this morning, Chengda Biology, the holding subsidiary of Chengda, Liaoning Province, will be deliberated on the board.
The latest data show that the number of shareholders in Chengda, Liaoning Province is 73100.
40 billion bull stocks suddenly fell by the limit.
Even if it fell by the daily limit this morning, the market capitalization of Chengda in Liaoning still has 39.13 billion yuan, which is still up 69% so far this year. It is this year's Daniel stock. Share prices have risen 200 per cent since the bottom in October 2018.
Liaoning Chengda, the current business is divided into medicine and health care, financial investment, supply chain services (trade) and energy development four major business sectors. Biomedicine is an important sector, contributing a lot to performance; Liaoning Chengda financial sector is important to hold shares in GF Securities Co., LTD., known as one of the "three treasures of Guangfa".
Liaoning Chengda still holds 1.25 billion shares of GF Securities Co., LTD., accounting for 16.4%, making it GF Securities Co., LTD. 's second largest shareholder. At this morning's closing price, the market value of the corresponding holdings is 19.7 billion yuan, equivalent to half of the current market value of Chengda in Liaoning Province.
Since the beginning of this year, the share price of Chengda in Liaoning has risen sharply, and the market believes that it has something to do with the listing of its subsidiary, Chengda Biology, which is a vaccine stock and is also a hot plate in the first half of this year.
Today, it is an important day for adult creatures, General Science and Technology Innovation Board.
Today's meeting of the spin-off subsidiary Shanghai Science and Technology Innovation Board
Science and Technology Innovation Board issued a notice showing that at 9: 00 this morning, the 80th review meeting of the listing Committee was held to examine two enterprises, including Liaoning Chengda Biology Co., Ltd. (abbreviated as Chengda Biology).
Liaoning Chengda holds a 60.74% stake in Chengda Biology. Chengda Biology is a biotechnology company specializing in the research, development, production and sale of human vaccines. From 2017 to 2018, Chengda ranked first in the world in terms of human rabies vaccine sales for two consecutive years. The company's core products include human rabies vaccine and inactivated Japanese encephalitis vaccine. At present, human rabies vaccine is the only rabies vaccine that can be injected with Zagreb2-1-1 in China, and adult inactivated Japanese encephalitis vaccine is the only domestic inactivated Japanese encephalitis vaccine on sale in China.
Changchun Hi-Tech also collapsed a few days ago.
Before Chengda in Liaoning Province fell to the limit today, the vaccine stock Changchun Hi-Tech also fell to the limit a few days ago. Changchun Hi-Tech still has a market capitalization of about 150 billion yuan, which is the white horse pharmaceutical stock favored by institutions. Recently, however, there has also been a relatively large pullback, with a callback of nearly 30%.
Other vaccine stocks also fell back a lot, Shanghai Fosun Pharmaceutical high fell more than 30%, Zhifei biology, Kangtai biology and so on also showed a large pullback.